17.08.2022 13:41:56
|
Quest Diagnostics Adds HCV Screening To Its New Obstetrics Test Panel
(RTTNews) - Quest Diagnostics (DGX) announced the launch of a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people for hepatitis C with other laboratory tests typically ordered during early pregnancy. The company noted that the new test panel follows a Quest Diagnostics Health Trends study with the CDC that revealed less than half of pregnant people are screened for hepatitis C as recommended under guidelines.
Damian "Pat" Alagia, Senior Medical Director, Women's Health, Quest Diagnostics, said: "By adding HCV screening to our obstetrics panel, physicians will be more likely to deliver guideline-based care that reduces HCV infection during pregnancy and fosters a positive outcome for the patient and their newborn."
For More Such Health News, visit rttnews.com.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!